9,666 results on '"Endometrial hyperplasia"'
Search Results
2. Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer
- Published
- 2024
3. Prospective Study for Endometrial Carcinoma and Hyperplasia in Childbearing-age Women
- Published
- 2024
4. Primary Prevention and Uterine Preservation in Premenopausal Women With Obesity and Endometrial Hyperplasia
- Author
-
Novo Nordisk A/S
- Published
- 2024
5. Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer (ECHO)
- Author
-
Jamie N. Bakkum-Gamez, Principal Investigator
- Published
- 2024
6. A Behavioral Intervention to Promote Primary Prevention and Uterine Preservation in Premenopausal Women With Obesity and Endometrial Hyperplasia
- Author
-
National Cancer Institute (NCI)
- Published
- 2024
7. CA-IX, p16, Proliferative Markers, and HPV in Diagnosing Cervical Lesions in Patients With Abnormal Cervical Cells
- Author
-
National Cancer Institute (NCI)
- Published
- 2024
8. GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Atypical Hyperplasia Patients
- Author
-
Xiaojun Chen, Professor
- Published
- 2024
9. Patient-derived Tumor-like Cell Clusters Predict Progesterone Sensitivity in Patients With Early Endometrial Cancer
- Author
-
Peking University, Beihang University, and Wang Jianliu, Professor, Doctoral supervisor, Chief physician, Vice President
- Published
- 2024
10. GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients
- Author
-
Xiaojun Chen, Professor
- Published
- 2024
11. Assessing the Benefit of Pipelle Biopsy in Patients With Postmenopausal Bleeding and an Atrophic-appearing Cavity
- Author
-
The Rotunda Hospital
- Published
- 2024
12. GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients
- Author
-
Xiaojun Chen, Professor
- Published
- 2024
13. The Use of Etonogestrel Contraceptive Implant as Treatment for Endometrial Hyperplasia Without Atypia: A Cohort Study
- Author
-
Organon
- Published
- 2024
14. Levonorgestrel-Releasing Intrauterine System in Treating Patients With Complex Atypical Hyperplasia or Grade I Endometrial Cancer
- Author
-
National Cancer Institute (NCI)
- Published
- 2024
15. Loxenatide Plus LNG-IUS in Endometrial Atypical Hyperplasia
- Author
-
Xiaojun Chen, Principal Investigator,Clinical Professor
- Published
- 2024
16. Levonorgestrel-Releasing Intrauterine System With or Without Everolimus in Treating Patients With Atypical Hyperplasia or Stage IA Grade 1 Endometrial Cancer (LEVER)
- Author
-
National Cancer Institute (NCI)
- Published
- 2024
17. Megestrol Acetate Plus Rosuvastatin in Young Women With Atypical Endometrial Hyperplasia
- Author
-
Xiaojun Chen, Principle investigator
- Published
- 2024
18. Effect of Stress Ball Use on Anxiety Level During Endometrial Biopsy Procedure
- Author
-
Yeliz DİNÇER, Dr, Principle İnvestigator
- Published
- 2024
19. Megestrol Acetate With or Without Pterostilbene in Treating Patients With Endometrial Cancer Undergoing Hysterectomy
- Author
-
National Cancer Institute (NCI)
- Published
- 2024
20. Analysis of assisted reproductive outcomes in patients with atypical endometrial hyperplasia and early‐stage endometrial cancer after fertility‐sparing treatment.
- Author
-
Li, Jiaheng, Li, Mengnuo, Li, Yijiang, Zhao, Xianling, Guan, Yichun, Yuan, Xiaoqiong, Du, Shanshan, Zhang, Caihua, Liu, Wenxia, and Ren, Bingnan
- Subjects
- *
ENDOMETRIAL hyperplasia , *INTRACYTOPLASMIC sperm injection , *REPRODUCTIVE technology , *FERTILIZATION in vitro , *EMBRYO transfer - Abstract
Objective Method Results Conclusion To explore the assisted reproductive outcomes of patients with atypical endometrial hyperplasia (AEH) and early‐stage endometrial cancer (EEC) who achieved complete remission after conservative treatment and to provide reference for clinical selection of appropriate conservative treatment.This retrospective cohort study included seven patients with EEC and 62 patients with AEH who underwent in vitro fertilization or intracytoplasmic sperm injection at the Reproductive Center of the Third Affiliated Hospital of Zhengzhou University between August 2015 and October 2023. The authors divided the participants into two groups based on the type of fertility‐sparing treatment received: the oral medication group and the levonorgestrel‐releasing intrauterine system (LNG‐IUS) group. The primary outcome was the cumulative clinical pregnancy rate. Secondary outcomes included clinical pregnancy rate per transfer cycle, embryo utilization rate, and high‐quality embryo rate.The LNG‐IUS group had a significantly higher rate of usable embryos compared with the oral medication group (80.8% vs 91.1%, P = 0.005) and also had a thinner endometrial thickness on the day of embryo transfer. The cumulative clinical pregnancy rate was higher in the LNG‐IUS group compared with the medication group (46.7% vs 78.9%, P = 0.037), and the difference was statistically significant.For patients with AEH and EEC with fertility needs, the conservative treatment method of LNG‐IUS can achieve better assisted reproductive outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
21. GnRH-a-based fertility-sparing treatment of atypical endometrial hyperplasia (AEH) and early endometrial carcinoma (EC) patients: a multicenter, open-label, randomized designed clinical trial protocol.
- Author
-
Liu, Qian, Zhou, Huimei, Yu, Mei, Cao, Dongyan, and Yang, Jiaxin
- Subjects
- *
ENDOMETRIAL hyperplasia , *LEVONORGESTREL intrauterine contraceptives , *MEDICAL societies , *BLOOD coagulation , *OBESITY in women , *CHILDBIRTH - Abstract
Background: Around 4% of women receive an endometrial cancer diagnosis before turning 40, mainly those without prior childbirth experience and a strong desire to preserve their ability to conceive. Consequently, for young patients diagnosed with atypical endometrial hyperplasia (AEH) or early endometrial carcinoma (EC), a fertility-preserving approach employing high-dose oral progesterone has been adopted. However, previous research has shown a notable relapse rate. Furthermore, the extended use of substantial oral progesterone doses may hinder ovarian function and raise the risk of weight gain, liver issues, blood clotting, and breast cancer. We previously assessed the clinical effectiveness and pregnancy outcomes of gonadotropin-releasing hormone agonist (GnRH-a) based re-treatment for women with EC and AEH who did not respond to oral progestin therapy but achieved favorable treatment results and reproductive outcomes. Methods: This study will be an open-label, two-armed, randomized, investigator-initiated multicenter trial evaluating the combination of GnRH-a with the levonorgestrel-releasing intrauterine system or the combination of GnRH-a with an aromatase inhibitor (comprising a subcutaneous GnRH-a injection every 4 weeks and daily oral letrozole 2.5 mg). A total of 226 participants will be randomly allocated to one of the two treatment groups in a 1:1 ratio. The primary objective is to determine the effectiveness of GnRH-a-based re-treatment in achieving a complete response (CR) at 24 weeks for patients with AEH or EC. Secondary objectives include assessing the pregnancy rate 12 weeks after treatment, as well as post-treatment pregnancy outcomes and the rate of recurrence. Ethics and dissemination: The protocol received approval from the Institutional Review Board of Peking Union Medical College Hospital and from boards at five other institutions. The trial will adhere to the principles outlined in the World Medical Association's Declaration of Helsinki and follow Good Clinical Practice standards. The trial results will be disseminated through publication in a peer-reviewed journal. Conclusions: Prospective evidence supporting conservative treatment for EC and AEH is limited. There is a need for new approaches that can achieve higher CR rates with fewer side effects. This trial will assess the effectiveness of GnRH-a-based fertility-sparing treatment in obese women and recurrent patients, offering a promising alternative for patients with EC and AEH. Trial registration number: Chinese Clinical Trial Registry ChiCTR2200067099. Registered on December 27, 2022. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
22. A multi-centre randomised controlled trial comparing megestrol acetate to levonorgestrel-intrauterine system in fertility sparing treatment of atypical endometrial hyperplasia.
- Author
-
Goh, Charissa Shu Ying, Loh, Michelle Jia Min, Lim, Whui Whui, Ang, Joella Xiahong, Nadarajah, Ravichandran, Yong, Tze Tein, Tong, Pearl, Yeo, Yen Ching, and Phoon, Jessie Wai Leng
- Subjects
- *
ENDOMETRIAL hyperplasia , *PREGNANCY outcomes , *RANDOMIZED controlled trials , *FERTILITY , *HUMAN fertility - Abstract
Purpose: The objective of the trial was to compare the regression rate of atypical endometrial hyperplasia (AEH) in patients treated with megestrol acetate (MA) vs. levonorgestrel-intrauterine device (LNG-IUS). We also aimed to assess the fertility and pregnancy outcomes in these patients. Methods: The study was a phase II multi-centre randomised controlled trial on the use of MA compared to LNG-IUS in the treatment of AEH conducted from January 2020 to January 2024 in Singapore. Women who were diagnosed with AEH and between 21 and 40 years old were included. The patients were randomised to receive either MA (160 mg orally daily) or LNG-IUS. The primary outcomes assessed were the regression rates at 3 months, 6 months and 9 months of treatment. The secondary outcomes assessed were the side effects, patient acceptability and fertility outcomes. Results: Thirty-six patients completed the trial. The overall regression rate was 88.9% by 9 months. There was no statistically significant difference in the 9-month complete regression rate between MA vs. LNG-IUS. There was also no significant difference in side effects and weight change between both arms. Nineteen patients were actively pursuing fertility after complete regression. There were 8 pregnancies achieved, with resultant 4 live births and 4 miscarriages. Conclusion: Our study confirms a high regression rate of AH with medical treatment. LNG-IUS is a non-inferior treatment compared to megestrol acetate. Successful pregnancy outcomes can be achieved after regression of AEH. Long-term studies of sufficient sample-size are needed to assess for fertility and pregnancy outcomes, risk of recurrence and long-term risk of malignancy. Trial registration number: The study was registered with the Health Science Authority (HSA) (License No.: CTA1900087) on September 5, 2019: https://eservice.hsa.gov.sg/prism/ct%5fr/enquiry.do?action=loadSpecificDetail. The trial was registered retrospectively on ClinicalTrials.gov (ID: NCT05492487) on April 7, 2022: https://clinicaltrials.gov/study/NCT05492487. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
23. Surgical nodal assessment for endometrial hyperplasia - A meta-analysis and systematic review.
- Author
-
Nahshon, Chen, Leitao, Mario M., Lavie, Ofer, Schmidt, Meirav, Younes, Grace, Ostrovsky, Ludmila, Assaf, Wissam, and Segev, Yakir
- Subjects
- *
SENTINEL lymph nodes , *ENDOMETRIAL hyperplasia , *LYMPH nodes , *ENDOMETRIAL cancer , *DATABASE searching - Abstract
Endometrial intraepithelial neoplasia (EIN) and atypical hyperplasia (AH) are recognized precursors for endometrial cancer (EC). Most current guidelines do not recommend the routine surgical evaluation of lymph nodes (LN), although recent studies indicate increased use of sentinel lymph node (SLN) biopsy in patients with a preoperative diagnosis of EIN/AH. We aimed to evaluate the rates of positive LN and its effect on the incidence of upstaging of EIN/AH patients, complications, and adjuvant treatment administration. A systematic review and meta-analysis was conducted in the following databases: MEDLINE(R) using the OvidSP interface and PUBMED, Embase, Web of Science, Clinicaltrials.gov and Cochrane Library. Included were studies investigating lymph node evaluation in patients diagnosed with EIN/AH, presenting results of LN assessment and/or comparisons of hysterectomy results with and without lymph node assessment. This analysis was registered at PROSPERO International prospective register of systematic reviews (CRD42023443598). A total of 447 studies were initially identified through database searching. The current analysis includes 7 studies comprising 1791 atypical endometrial hyperplasia patients who underwent hysterectomy with lymph node assessment. The incidence of positive lymph nodes among those who had undergone any LN evaluation was found to be 1.1% (95% CI 0.3%–2%). The rate of positive LNs was 1.4% (95% CI 0.2%–1.9%) among those who had undergone specifically SLN. 319 (44.3%, 95% CI 34%–54.7%) patients of the patients initially diagnosed with EIN/AH (n = 699), were finally upgraded to EC diagnosis. Fifteen percent of the final EC diagnosed patients were treated with adjuvant treatment. No significant difference regarding complication rates was noticed. Our review indicates that the rate of metastatic LNs is <2% in patients undergoing surgical nodal evaluation for EIN/AH. However, the rate of complication for SLN mapping is low and may have an impact on postoperative therapy decisions in those diagnosed with malignancy. • We found that the rate of metastatic lymph nodes is <2% in patients undergoing surgical nodal evaluation for EIN/AH. • With that said, no significant difference regarding complication rates was noticed and overall complication rates were low. • Lymph node assessment may have an impact on postoperative therapy decisions in those diagnosed with malignancy. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
24. Comparative effects of different treatments based on the levonorgestrel intrauterine system in endometrial carcinoma and endometrial hyperplasia patients: a network meta-analysis.
- Author
-
Tao, Muheng, Wu, Tingting, Zhou, Xin, Du, Xiurong, Ling, Kaijian, and Liang, Zhiqing
- Subjects
- *
LEVONORGESTREL intrauterine contraceptives , *ENDOMETRIAL hyperplasia , *ENDOMETRIAL cancer , *TREATMENT effectiveness , *UTERINE hemorrhage - Abstract
Objective: Levonorgestrel intrauterine system (LNG-IUS) has been widely used in patients with endometrial carcinoma (EC), endometrial hyperplasia without atypical (EH), and atypical endometrial hyperplasia (AEH). The purpose of our Network meta-analysis (NMA) is to evaluate the efficacy of the treatments based on the LNG-IUS in patients with EC and EH with or without atypical. Methods: We examined PubMed, EMBASE, Web of Science and the Cochrane Library up to 22 April 2024 to determine studies reporting treatment outcomes in EC and EH patients receiving LNG-IUS therapy, LNG-IUS + metformin (MET), oral progestins (OP), etc. We used EndNote 9 to select studies, Jadad scale and NOS scale to assess quality, stata(16.0) and R (4.3.1) to analysis the data. Results: Overall, 28 studies involving 3752 patients were included in our NMA. As for EH patients, LNG-IUS (RR 1.21; 95% CrI [1.11, 1.34]) and LNG-IUS + MET (RR 323.57; 95% CrI [1.61, 214,223,188.1])] significantly increased CR rate in comparison with OP. Based on SUCRA, LNG-IUS + OP was the best treatment to improve CR(SUCRA = 67.2%) in patients with EC, whereas LNG-IUS + MET was superior in increasing CR (SUCRA = 99.8%) than any other treatments for EH patients. Besides, the ranking based on SUCRA illustrated that LNG-IUS alone was the best choice to raise CR rates (SUCRA = 76.7%) for AEH patients. In head-to-head meta-analysis, OP has a higher progression rate (RR 4, 95% CI 1.89–8.46, p = 0.062; I2 = 71.3%), a higher nausea rate (RR 1.93, 95% CI 1.24–3.01, p = 0.187; I2 = 40.4%) than LNG-IUS in patients with EH. In contrast, LNG-IUS had a irregular vaginal bleeding rates (RR 0.76, 95% CI 0.64–0.90, p = 0.034; I2 = 77.7%) than OP in EH patients. In addition, as for AEH patients, OP has a higher persistence rate (RR 4.31, 95% CI 1.43–13.00, p = 0.93; I2 = 0.0%) than LNG-IUS. Conclusion: According to the NMA, LNG-IUS related studies are feasible for conservative therapy in patients with EC and EH with or without atypical. Therefore, concerning the curative effect, we recommend LNG-IUS-based treatments as the best conservative therapy for EC and EH patients. However, future studies require large sample sizes and more outcomes to further evaluate the differences of treatment selections based on LNG-IUS. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
25. Endometrial Polyp-Like Lesions Arising From Adenomyosis: Report of 5 Cases.
- Author
-
St. Louis, Hailee, Renshaw, Idris L., and Fadare, Oluwole
- Subjects
- *
ENDOMETRIAL hyperplasia , *SENTINEL lymph nodes , *HYSTERO-oophorectomy , *UTERINE prolapse , *ENDOMETRIOSIS , *ENDOMETRIUM - Abstract
This article discusses a study on endometrial polyp-like lesions arising from adenomyosis. Adenomyosis is a common gynecologic disease characterized by the presence of endometrial glands and stroma within the myometrium. The study presents 5 cases of this distinctive lesion and expands their pathologic spectrum. The patients ranged in age from 47 to 75 years and their uteri were resected for various indications. The study describes two patterns of endometrial polyp-like lesions and discusses their histological features. The article concludes by stating that these cases further expand the understanding of endometrial polyp-like lesions arising from adenomyosis. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
26. Immunohistochemical Investigation of P16 Expression in Curettage Biopsies.
- Author
-
Yurtkal, Aslıhan, Canday, Müjde, and Havadar, Hatice Beşeren
- Subjects
CURETTAGE ,DIAGNOSIS of endometrial cancer ,IMMUNOHISTOCHEMISTRY ,PROTEIN expression ,ENDOMETRIAL hyperplasia - Abstract
Copyright of Osmangazi Journal of Medicine / Osmangazi Tip Dergisi is the property of Eskisehir Osmangazi University and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2024
- Full Text
- View/download PDF
27. Progression of fertility-sparing treatment for atypical endometrial hyperplasia in a woman with lynch syndrome: a case report and review of the literature.
- Author
-
Ya-Ting Hsu and Chi-Hau Chen
- Subjects
LITERATURE reviews ,PREGNANCY outcomes ,DISEASE relapse ,ENDOMETRIAL cancer ,GENETIC mutation ,HEREDITARY nonpolyposis colorectal cancer ,ENDOMETRIAL hyperplasia - Abstract
Endometrial cancer in Lynch syndrome is characterized by a higher incidence, younger age at onset, and increased recurrence rates compared to sporadic cases, while the safety and efficacy of fertility-sparing treatments remain uncertain. This case report presents the oncology outcome of fertilitypreserving treatment in a 39-year-old woman diagnosed with Lynch syndrome and atypical endometrial hyperplasia. Initially, she responded favorably to fertility-preserving treatment but subsequently experienced disease relapse and rapid progression during retreatment. Final pathology revealed endometrial cancer with metastasis to the right ovary, categorized as FIGO 2023 stage IIIA1. This population's unique molecular mechanisms and genetic mutations warrant special consideration when opting for fertility-sparing treatment. We have reviewed and summarized the oncology and pregnancy outcomes among Lynch syndrome and MMR-deficient patients through previous literature. However, no studies have investigated retreatment after recurrence in Lynch syndrome. Our case highlights the potential risks associated with retreatment following relapse. Vigilant monitoring and prompt consideration of surgical intervention are recommended upon disease relapse. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
28. Expression Patterns of Cytokeratins (CK7, CK20, CK19, CK AE1/AE3) in Atypical Endometrial Hyperplasia Coexisting with Endometrial Cancer.
- Author
-
Vasilevska, Danuta, Rudaitis, Vilius, Lewkowicz, Dorota, Širvienė, Dominika, Mickys, Ugnius, Semczuk, Marek, Obrzut, Bogdan, and Semczuk, Andrzej
- Subjects
- *
ENDOMETRIAL hyperplasia , *UTERINE tumors , *ENDOMETRIAL cancer , *UNIVERSITY hospitals , *IMMUNOSTAINING - Abstract
Few studies have evaluated cytokeratin's (CK) staining patterns in atypical endometrial hyperplasia (AEH) coexisting with early-stage endometrial cancer (EC). We aimed to assess the staining patterns of selected CKs (CK7, CK19, CK20, CK AE1/AE3) in 74 patients with coexisting AEH and EC by independently analyzing both morphological variables. Specimens were collected from women with AEH and EC who underwent surgical interventions between 2012 and 2019 at the Department of Obstetrics and Gynecology of Vilnius University Hospital "Santaros Klinikos" in Vilnius, Lithuania. Immunostaining was also qualitatively classified as being heterogeneous or intense. The results revealed heterogeneous CK7 expression in all AEH cases and intense staining in 95.95% cases of AEH. The heterogeneous expression of CK7 was detected in all EC specimens. Intense CK7 expression was observed in 95.09% cases of EC G1 and in all G2 ECs. Heterogenous CK19 expression was present in all AEH specimens with intense staining in 92.42% of cases. Heterogeneous CK19 expression was observed in all EC samples with intense expression in 86.27% cases of EC G1 and 100% cases of EC G2. Interestingly, a significant relationship was found when comparing the heterogeneous expression of CK19 between AEH and well-differentiated EC. A significant difference was reported in the intense expression of CK AE1/AE3 (p = 0.031; p = 0.029) between AEH and G2 ECs and in the intense expression of CK AE1/AE3 between G1 and G2 ECs. CK20 staining was not a characteristic feature for AEH and early-stage EC. CK staining is present either in AEH or in early-stage endometrioid-subtype EC in different manners. Heterogeneous CK19 expression was significantly more common in AEH than in EC. CK20 expression was not associated with either AEH nor early-stage EC. An intense expression of CK AE1/AE3 was mainly present in moderately differentiated ECs, whereas the intense reactivity of AE1/AE3 showed a significant difference in well to moderately differentiated uterine tumors. The clinical implication of CK staining may aid in the more accurate diagnosis of AEH and early-stage EC as well as detect micrometastases leading to better oncological outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
29. Expressions and clinical significances of miR-23a and APAF-1 in endometrial carcinoma.
- Author
-
ZHANG Qiong and HE Suli
- Subjects
- *
ENDOMETRIAL cancer , *GENE expression , *OVERALL survival , *CANCER prognosis , *CANCER cell differentiation , *ENDOMETRIAL hyperplasia , *CANCER patients - Abstract
Objective To observe the expression changes of micro RNA-23a(miR-23a) and apoptotic protease-activating factor-1 (APAF-1) in endometrial carcinoma tissues and analyze its clinical significance. Methods 123 specimens of endometrial carcinoma in our hospital from May 2018 to May 2020 were selected as endometrial carcinoma group, and the para cancerous tissue was selected as the normal group. Expression of miR-23a and APAF-1 were examined in endometrial tissues; the relationship between miR-23a and APAF-1 and the clinicopathology of patients and the correlation between the two were analyzed; Kaplan-Meier method was used to analyze the survival of patients with endometrial cancer. Results Compared with the normal group, the expression level of miR-23a in endometrial carcinoma group was significantly increased, the expressions of APAF-1 mRNA and protein decreased significantly (P < 0.05); miR-23a and APAF-1 were significantly correlated with clinical stage, histological differentiation and myometrial invasion (P < 0.05); Pearson analysis showed that miR-23a was negatively correlated with APAF-1 (P < 0.05); Kaplan-Meier curves showed that PFS and OS were significantly higher in the miR-23a low-expression group as well as the APAF-1-positive expression group than in the miR-23a high-expression group and the APAF-1-negative expression group(P < 0.05). Conclusion The expression level of miR-23a is increased and APAF-1 expression is decreased in endometrial carcinoma, both of which correlate with endometrial cancer progression and patient prognosis, are expected to be biomarkers for clinical assessment of disease progression and prognosis in early-stage patients. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
30. Update on the oncologic and obstetric outcomes of medroxyprogesterone acetate treatment for atypical endometrial hyperplasia and endometrial cancer.
- Author
-
Tamauchi, Satoshi, Nakagawa, Atsushi, Yoshida, Kosuke, Yoshihara, Masato, Yokoi, Akira, Yoshikawa, Nobuhisa, Niimi, Kaoru, and Kajiyama, Hiroaki
- Subjects
- *
ENDOMETRIAL hyperplasia , *BODY mass index , *DISEASE relapse , *ENDOMETRIAL cancer , *ORAL drug administration - Abstract
Aims Methods Results Conclusions To evaluate the safety and effectiveness of high‐dose oral medroxyprogesterone acetate (MPA) therapy as a fertility‐sparing treatment for patients diagnosed with atypical endometrial hyperplasia (AEH) and endometrioid carcinoma G1 without myometrial invasion (G1EC). Particular attention was given to the extended administration and readministration of MPA for patients with persistent disease following initial treatment and those with recurrence.We conducted a retrospective analysis of data from 79 patients who underwent daily oral MPA treatment between 2005 and 2024 at Nagoya University Hospital. Patient characteristics, treatment outcomes, factors contributing to recurrence, and post‐MPA therapy pregnancies were examined.MPA therapy achieved a remarkable complete response (CR) rate of 91.1%. The median time to achieve CR was 26.0 and 40.0 weeks for AEH and G1EC patients, respectively. Importantly, 27 patients (39.7%) attained CR after more than 6 months of treatment, including 8 patients (11.8%) who achieved CR after more than a year of treatment. The recurrence rates were 52.9% for AEH and 64.7% for G1EC. Twenty eight patients resumed MPA treatment, and 23 achieved second CR. Notably, recurrence was not associated with clinical factors such as age, body mass index, or post‐CR pregnancy. Among patients who attempted pregnancy after achieving CR, 22 live births were successfully achieved.High‐dose oral MPA therapy demonstrated both safety and efficacy for preserving fertility in patients with AEH and G1EC, resulting in a high CR rate. MPA extension and readministration proved to be beneficial strategies for managing patients with recurrence and persistent disease following initial treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
31. Clinicopathological Aspects of Dilation and Curettage (D&C) Biopsies Taken from Patients Living at High Altitude in Taif, KSA, with a Special Emphasis on Chronic Endometritis.
- Author
-
Hagag, Howaida M., Ismail, Khadiga A., Almutairi, Mashael M., Alnefaie, Bushra I., Alajmani, Seham H., Altalhi, Ashwaq M., Alkhamash, Abdulaziz H., Althobaiti, Naif S., Alhumaidi, Mohammed Awadh, Bawahab, Ahmed Abdulwahab, and Hasan, Abdulkarim
- Subjects
- *
BLOOD cell count , *UTERINE hemorrhage , *ENDOMETRIAL hyperplasia , *DILATATION & curettage , *HEMATOXYLIN & eosin staining , *ENDOMETRIUM - Abstract
Background: Chronic endometritis (CE) is a persistent inflammation of the uterine lining. Although it has a minimal clinical presentation, CE adversely affects the reproductive ability of women. The aims of this study were to detect pathological endometrial patterns in D&C biopsies and to evaluate chronic endometritis in patients living in a high-altitude area (1800 m above sea level) in order to determine the clinical pathological features and prevalence. Materials and methods: A cross-sectional study conducted at King Faisal Maternity Hospital included 100 samples of D&C biopsies from women complaining of various gynecological symptoms not due to gestational causes. The biopsies underwent tissue processing, H&E staining, and CD138 detection. Blood samples were taken for serological detection of infectious diseases, complete blood count, and chemical parameters. Results: The mean age of women in the study with CE was 48.5 ± 8.5 years, and that of those without CE was 46.9 ± 9.7 years. The most common complaints were abnormal uterine bleeding, accounting for 83%. CE was present in 8% of cases, and there was a nonsignificant difference in hematological parameters between women with CE and those with other pathological diagnoses. There were also nonsignificant differences in chemical parameters, except for FSH and LH levels, which showed a significant difference, with p-values of 0.05 and 0.02, respectively. It can be concluded that the most common gynecological complaint of women in this study was abnormal uterine bleeding. Conclusions: The most commonly diagnosed pathological endometrial disorder in D&C biopsies was disordered proliferative endometrium, followed by endometrial polyps and endometrial hyperplasia. All of these are usually associated with hormonal disturbance, which appeared to be very common in the women in this study. The prevalence of chronic endometritis detected in our study was 8%, which is relatively high. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
32. Comprehensive next-generation sequencing identifies novel putative pathogenic or likely pathogenic germline variants in patients with concurrent tubo-ovarian and endometrial serous and endometrioid carcinomas or precursors.
- Author
-
Aisagbonhi, Omonigho, Ghlichloo, Ida, Hong, Duncan S., Roma, Andres, Fadare, Oluwole, Eskander, Ramez, Saenz, Cheryl, Fisch, Kathleen M., and Song, Wei
- Subjects
- *
CANCER genes , *FALLOPIAN tubes , *BENIGN tumors , *NUCLEOTIDE sequencing , *ENDOMETRIAL hyperplasia ,CANCER susceptibility - Abstract
Endometrial serous carcinoma (ESC) and tubo-ovarian high-grade serous carcinoma (HGSC) are characterized by late-stage presentation and high mortality. Current guidelines for prevention recommend risk-reducing salpingo-oophorectomy (RRSO) in patients with hereditary mutations in cancer susceptibility genes. However, HGSC displays extensive genetic heterogeneity with alterations in 168 genes identified in TCGA study, but current germline testing panels are often limited to the handful of recurrently mutated genes, leaving families with rare hereditary gene mutations potentially at-risk. To determine if there are rare germline mutations that may aid in early identification of more patients at-risk for ESC and/or HGSC by evaluating patients with concurrent ESC, HGSC or precursor lesions, and endometrial atypical hyperplasia (CAH) or low-grade endometrial endometrioid adenocarcinoma (LGEEA). We performed targeted next-generation sequencing using TSO 500, a 523 gene panel, on formalin-fixed paraffin-embedded tumor and matched benign non-tumor tissue blocks from 5 patients with concurrent ESC, HGSC or precursor lesions, and CAH or LGEEA. We identified germline pathogenic, likely pathogenic or uncertain significance variants in cancer susceptibility genes in 4 of 5 patients – affected genes included GLI1 , PIK3R1 , FOXP1 , FANCD2 , INPP4B and H3F3C. Notably, none of these genes were included in the commercially available germline testing panels initially used to evaluate the patients at the time of their diagnoses. Comprehensive germline testing of patients with concurrent LGEEA or CAH and ESC, HGSC or precursor lesions may aid in early identification of relatives at-risk for cancer who may be candidates for RRSO with hysterectomy. • High-grade serous carcinoma (HGSC) carries a high mortality. • Goal: Expand upon methods for early identification of potential candidates for risk-reducing salpingo-oophorectomy (RRSO). • We performed comprehensive NGS on tumor and normal tissues. • We identified rare germline variants in patients with concurrent endometrial and tubo-ovarian cancers. • Comprehensive genetic profiling may aid in early identification of patient relatives who may benefit from RRSO. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
33. Advances in the use of organoids in endometrial diseases.
- Author
-
Liu, Yaofang, Sun, Yue, and Cheng, Shaolong
- Subjects
- *
ENDOMETRIAL diseases , *ORGANOIDS , *PATHOGENESIS , *DISEASE progression , *ENDOMETRIUM , *ENDOMETRIAL hyperplasia , *UTERINE hemorrhage - Abstract
The endometrium undergoes cyclical changes in response to hormones and there is a certain degree of heterogeneity among individuals. In vivo identification of the physiologic changes of the endometrium and the pathologic process of related diseases is challenging. There have been recent advances in the use of organoids that mimic the characteristics of the corresponding organs and the morphologic, functional, and personalized characteristics involved in different stages of diseases. In this paper, we discuss the process of creating endometrial organoids, cell sources, types of extracellular matrices, and their application in the study of physiologic endometrial states and various diseases. Synopsis: The paper explores endometrial organoids, their use in studying physiologic states and diseases, and recent advancements in this field. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
34. Oncological and reproductive outcomes of endometrial atypical hyperplasia and endometrial cancer patients undergoing conservative therapy with hysteroscopic resection: A systematic review and meta‐analysis.
- Author
-
Zhao, Shuangshuang, Zhang, Jingying, Yan, Ye, Tian, Lina, Chen, Lingli, Zheng, Xingyu, Sun, Yiqing, Tian, Wenyan, Xue, Fengxia, and Wang, Yingmei
- Subjects
- *
HYSTEROSCOPIC surgery , *ENDOMETRIAL hyperplasia , *CONSERVATIVE treatment , *ENDOMETRIAL cancer , *REPRODUCTIVE health , *INTRAUTERINE contraceptives , *HYSTEROSCOPY - Abstract
Introduction: Our objective was to conduct a systematic review and meta‐analysis of studies evaluating the oncological and reproductive outcomes of patients with endometrial atypical hyperplasia (AH) and endometrioid endometrial cancer (EEC) undergoing conservative therapy with hysteroscopic resection (HR). Material and methods: This study followed the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) statement for systematic reviews and meta‐analyses. The study strictly followed the methodological framework proposed by the Cochrane Handbook and was retrospectively registered in PROSPERO (CRD42023469986). Searches were conducted in PubMed, Embase, and the Cochrane Library, from inception to October 10, 2023. A checklist based on items of the Newcastle–Ottawa Scale and the Methodological Index for Non‐randomized Studies was used for quality assessment. The primary end points for this meta‐analysis were complete response (CR), pregnancy, and live birth rates following HR‐based therapy in patients with EEC or AH. The secondary end point was the recurrence rate (RR). Results: Twenty‐one articles involving 407 patients with clinical stage IA, low or intermediate grade, EEC, and 444 patients with AH managed with HR‐based conservative treatment were included for this systematic review. CR to HR‐based conservative therapy was achieved in 88.6% of patients with EEC and 97.0% of patients with AH. Of these, 30.6% and 24.2%, respectively, had live births. The overall pooled disease RR was 18.3% and 10.8% in patients with EEC and AH, respectively. Further subset analyses revealed that EEC patients with body mass index (BMI) ≤28 kg/m2 had higher CR rates as well as higher chances of pregnancy and live birth (91.6% CR, 32.9% pregnancy, 31.1% live birth) compared with patients with BMI >28 kg/m2 (86.4% CR, 28.4% pregnancy, 23.0% live birth). The HR followed by oral progestogen subgroup had higher CR rates and higher chances of pregnancy and live birth (91.8% CR, 36.3% pregnancy, 28.2% live birth) than the HR followed by the levonorgestrel intrauterine system subgroup (82.5% CR, 25.3% pregnancy, 16.3% live birth). Conclusions: Hysteroscopic resection followed by progestins appears to be a promising choice for fertility‐sparing treatment in young patients with AH and EEC, with effective and safe responses. The live birth rate remains to be improved by providing medical guidance and encouragement. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
35. Oleic acid induces mitochondrial-mediated cell death via mPT pore and protects against estradiol benzoate-induced endometrial hyperplasia in female Wistar rats.
- Author
-
Olowofolahan, Adeola Oluwakemi, Aina, Oluwasanmi Olayinka, and Olorunsogo, Olufunso Olabode
- Subjects
- *
LABORATORY rats , *TUMOR necrosis factors , *ENDOMETRIAL hyperplasia , *CHILDBEARING age , *OLEIC acid , *CELL death - Abstract
Endometrial hyperplasia (EH) is a female gynecological disorder which occurs in women of reproductive age. It has been attributed to excessive exposure to estrogen and this has been linked to a loss of apoptotic signaling, thereby leading to malignancy. The available treatment options are quite expensive and associated with some side effects, thus; a need for better therapy. Oleic acid(OA) has been reported to have anticancer properties in some cancer cells. However, this study investigated its effect on mitochondrial-mediated cell death via mPT pore and estradiol benzoate (EB)-induced EH using rat model. Forty-six virgin female Wistar strain rats weighing between 180-200 g (7 weeks old) were used for this study. Mitochondria were isolated by differential centrifugation and exposed to different concentrations of OA. The mPT pore opening, cytochrome c release (CCR) and mitochondrial ATPase (mATPase) activity were assessed spectrophotometrically. Thirty-six female rats were equally grouped into six: A(Control), B(OA: 10 mg/kg), C(OA: 30 mg/kg), D(EB):(2 mg/kg), E(EB + OA 10 mg/kg) and F(EB + OA 30 mg/kg). The rats were orally treated for twelve weeks except for EB which was by intra-peritoneal injection. The cholesterol, estradiol, follicle-stimulating hormones, luteinizing hormones, malondialdehyde, superoxide dismutase, reduced glutathione, Interleukin-1β, Interleukin-6, Tumor Necrosis Factor alpha, and Interleukin-10β were determined using ELISA kits. Histological assessment of the uterine sections was determined. Oleic acid effected significant induction of mPT pore opening, CCR and mATPase activity. The cholesterol, sex hormones and inflammatory cytokines levels were significantly increased in the EB-treated group, which were remarkably reduced by OA treatment. The antioxidant indices were also restored by OA. Histology revealed severe EH and abundant deposition of collagens in the EB-treated group, which were attenuated by OA treatment. Treatment with OA mitigated the induced hyperplasia and reduced the collagen deposition. This study suggests antiproliferative potentials of OA in EB-induced EH as it induces mitochondrial-mediated cell death and protects against EB-induced EH in female Wistar rats. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
36. Added Value of Transvaginal Real-Time Shear Wave Elastography in the Diagnosis of Endometrial and Sub-endometrial Lesions.
- Author
-
Soliman, Basma Kamal, Hasan, Amira Abdelaziz, Elfawal, Magdy Mohamed, and Amin, Mohamed Ibrahim
- Subjects
- *
SHEAR waves , *ENDOMETRIAL hyperplasia , *ENDOMETRIAL cancer , *ELASTOGRAPHY , *WOMEN patients , *UTERINE hemorrhage - Abstract
Background: Endometrial and sub-endometrial lesions are a common cause of abnormal uterine bleeding. Ultrasound is a reliable diagnostic tool for those lesions, but not all patients exhibit definite changes in ultrasound, making additional techniques necessary. Elastography, such as shear wave elastography (SWE), can assess the mechanical properties of the endometrial lesions and provides a quantitative measure of tissue stiffness and so aids in differentiating different pathologies. Our study aimed to determine the added value of SWE in diagnosis of different endometrial and sub-endometrial lesions. Methods: Thirty-six female patients presented with abnormal uterine bleeding (AUB) with pathologically proven endometrial and sub-endometrial pathologies were included in this prospective study and assessed with transvaginal SWE. The mean elasticity values (E mean) in Kilopascals (KPa), and the ratio of the mean elasticity of the lesion to the mean myometrial elasticity (E/M ratio) were calculated in variable lesions. Results: There was a statistically significant difference in the E mean (P > 0.001) as well as the E/M ratio of different endometrial and sub-endometrial lesions (P > 0.001). E mean value in endometrial carcinoma (EC) was 39.79 ± 3.65, endometrial hyperplasia (EH) was 24.24 ± 1.52, and endometrial polyp was 15.74 ± 2.71. While that of submucosal fibroid was 59.36 ± 12.84 and adenomyoma (AM) was 52.15 ± 4.44. In the analysis of the subgroups, the E/M ratio of uterine polyp (0.36 ± 0.07) was statistically significantly lower than other subgroups (P >0.01), while submucosal leiomyoma (1.8 ± 0.27) and focal adenomyoma (1.37 ± 0.07) had significantly higher values than other subgroups (P < 0.01). Conclusions: Shear wave elastography is an effective additional method in differentiating between benign and malignant endometrial and sub-endometrial lesions when combined with conventional ultrasonography. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
37. Predicting Endometrial Hyperplasia and Endometrial Cancer on Recurrent Abnormal Uterine Bleeding.
- Author
-
Unyamanee Veeranaraphanit, Nungrutai Saeaib, and Wisarut Srisintorn
- Subjects
- *
RECEIVER operating characteristic curves , *DISEASE risk factors , *ENDOMETRIAL cancer , *ODDS ratio , *ENDOMETRIAL hyperplasia , *LOGISTIC regression analysis , *UTERINE hemorrhage - Abstract
OBJECTIVE: To develop predictive models for endometrial hyperplasia and endometrial cancer in patients with recurrent abnormal uterine bleeding (AUB). METHODS: This retrospective cohort study analyzed patients with recurrent AUB who had previous endometrial sampling that showed benign results between January 2013 and December 2021. A model was constructed from the significant factors associated with endometrial hyperplasia and endometrial cancer using multivariate logistic regression. Risk scores were calculated from the log odds of each significant predictive factor and were subsequently subcategorized into risk groups. The overall performance and internal validation of the model were assessed with the area under the receiver operating characteristic curve (AUC) and bootstrap methods. RESULTS: Of the total 456 patients with recurrent AUB, endometrial hyperplasia and endometrial cancer were detected in 8.3% and 2.2% of cases, respectively. The average interval between the first and second endometrial samplings was 25.1 months. Factors significantly associated with endometrial hyperplasia and endometrial cancer included age older than 45 years (odds ratio [OR] 2.86, 95% CI, 1.31-7.03), nulliparity (OR 3.50, 95% CI, 1.76-6.85), a history of endometrial polyp (OR 3.69, 95% CI, 1.93-7.05), and an interval of less than 12 months between sampling (OR 2.36, 95% CI, 1.25-4.42). Predictive factors were scored and categorized into three groups: 0-3, 5-8, and 9-11 points. The corresponding risks for endometrial hyperplasia and endometrial cancer in these groups were 4.7%, 15.5%, and 57.1%, respectively. The AUC was 73.1%, with a mean absolute error of 0.01. CONCLUSION: Endometrial hyperplasia and endometrial cancer occur at low incidence among one-fifth of patients with AUB who experience recurrent bleeding. Older age, nulliparity, a history of endometrial polyps, and an interval of less than 12 months between samplings are predictive factors for endometrial hyperplasia and endometrial cancer in this cohort. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
38. Mammary and reproductive tract tumours and tumour-like lesions of 286 small pet mammals: a retrospective study.
- Author
-
Paździor-Czapula, Katarzyna, Mikiewicz, Mateusz, Fiedorowicz, Joanna, and Otrocka-Domagała, Iwona
- Subjects
RABBITS ,GRANULOSA cells ,GENITALIA ,ENDOMETRIAL hyperplasia ,FERRET ,GUINEA pigs ,HAMSTERS - Abstract
Small mammals are very popular companion animals, and the incidence of particular tumour types in these animals is the subject of extensive research. We carried out a retrospective and comparative analysis of the incidence of reproductive tract and mammary tumours and tumour-like lesions collected from 103 pet rabbits, 75 pet rats, 71 guinea pigs, 12 mice, 11 hamsters, eight African pygmy hedgehogs, four ferrets and two chinchillas. The results indicate that uterine tumours and tumour-like lesions are common in pet rabbits, guinea pigs and African pygmy hedgehogs. In pet rabbits, the most common uterine tumour was endometrial adenocarcinoma, while in guinea pigs benign lesions predominated (ie, leiomyoma, endometrial adenoma, cystic endometrial hyperplasia and deciduoma). Uterine tumours in African pygmy hedgehogs included adenosarcomas and endometrial polyps. Ovarian lesions were found only in guinea pigs (ovarian rete adenomas, rete cysts) and African pygmy hedgehogs (mostly granulosa cell tumours), while testicular tumours were diagnosed in pet rabbits, one pet rat and one guinea pig. Mammary tumours were common in pet rabbits, pet rats, guinea pigs, mice, hamsters and African pygmy hedgehogs. In pet rats, the most common mammary tumour was fibroadenoma, while in other animals carcinomas predominated. In guinea pigs and, to a lesser extent, in pet rats, a significant percentage of mammary tumours occurred in males. Guinea pigs seem to be predisposed to mammary tumours of ductal origin. This study describes for the first time uterine angioleiomyoma in the pet rabbit and mammary spindle cell carcinoma in the Djungarian hamster and chinchilla. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
39. An altered uterine microbiota with endometrial hyperplasia.
- Author
-
Ying, Xue, Xu, Gufeng, Wang, Huiyun, and Wang, Yue
- Subjects
- *
ENDOMETRIAL hyperplasia , *ENDOMETRIAL cancer , *SERRATIA - Abstract
Background: Endometrial hyperplasia (EH) is a precursor to endometrial cancer, and the role of the microbiome in its development is unclear. Results: The present study investigated the uterine microbiome in patients with benign uterine conditions and endometrial hyperplasia. A significant structural shift in the uterine microbiome of patients with endometrial hyperplasia compared to those with benign conditions was found. Delftia, Serratia and Stenotrophomonas were significantly enriched in endometrial hyperplasia samples and associated with the presence of endometrial hyperplasia. Conclusions: The novel finding suggested that increased abundance of Delftia, Serratia and Stenotrophomonas is associated with the presence of endometrial hyperplasia. Further investigation is needed to determine the value of these microbes as biomarkers for endometrial hyperplasia. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
40. 子宮全摘後の S 状結腸憩室炎に起因する S 状結腸腟瘻の 1 例.
- Author
-
辻尾 元, 貝崎 亮二, 中田 真一, and 国本 友浩
- Subjects
- *
VAGINAL fistula , *SIGMOID colon , *ENDOMETRIAL hyperplasia , *HYSTERO-oophorectomy , *DIVERTICULUM - Abstract
A 61-year-old female with a history of undergoing total hysterectomy and bilateral salpingo-oophorectomy for atypical endometrial hyperplasia at the age of 55 presented at our hospital because of pus-like discharge from the vagina lasting for three weeks. Abdominal enhanced CT scan revealed multiple diverticula of the sigmoid colon with surrounding inflammation. The sigmoid colon was connected to the vaginal stump with a band-like structure and the formation of a fistula was suspected. Colposcopy revealed a fistula on the vaginal end, and contrast examination from the vagina showed that the fistula was connected to the sigmoid colon. Under the diagnosis of sigmoid-vaginal fistula secondary to diverticulitis the of sigmoid colon, we performed laparoscopic rectal low anterior resection and ileostomy construction. The vaginal side of the fistula was closed with sutures. Closure of the ileostomy was performed four months postoperatively [ABSTRACT FROM AUTHOR]
- Published
- 2024
41. Effects of melatonin on disease improvement and serum levels of pro-inflammatory cytokines in patients with non-atypical endometrial hyperplasia.
- Author
-
Aslany, Neda, Vahedpour, Zahra, Rahimi, Habibollah, Masjedi, Mohsen, and Motedayyen, Hossein
- Subjects
- *
ENDOMETRIAL hyperplasia , *MELATONIN , *PROGESTERONE receptors , *UTERINE hemorrhage , *PROGESTERONE , *CYTOKINES - Abstract
Endometrial hyperplasia (EH), an abnormal proliferation of the endometrial cells, is considered as one of the most common causes of abnormal uterine bleeding. Previous studies have reported that melatonin plays a fundamental role in disease treatment. This study aimed the comparison of the effects of progesterone, as the most common therapeutic approach, and melatonin with progesterone alone in improvement of non-atypical endometrial hyperplasia (NEH) and changes in pro-inflammatory cytokine levels. Study population consisted of 40 patients with NEH. Patients were divided into two groups, including 20 subjects treated with melatonin and progesterone and 20 individuals treated with progesterone alone. The blood and endometrial sampling was performed from participants before and after a three-month treatment. The histological examination was microscopically done. The serum levels of tumor necrosis factor-alpha (TNF-α) and interferon-gamma (IFN-γ) were measured using ELISA. There was no significant difference in the diabetes status and mean age between patients treated with progesterone and melatonin and those treated with progesterone alone. The improvement rate in the EH was significantly higher in individuals treated with progesterone and melatonin than those treated with progesterone alone (p < 0.05). Additionally, the patients treated with progesterone and melatonin showed significant increases inIFN-γ and TNF-αlevels compared to the control group (p < 0.001-P < 0.05). Melatonin supplementation has a beneficial effect in the treatment of EH due perhaps to enhance the level of IFN-γ and TNF-α. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
42. Comprehensive Evaluation of a Levonorgestrel Intrauterine Device (LNG-IUD), Metformin, and Liraglutide for Fertility Preservation in Endometrial Cancer: Protocol for a Randomized Clinical Trial.
- Author
-
Leipold, Gergő, Tóth, Richárd, Hársfalvi, Péter, Lőczi, Lotti, Török, Marianna, Keszthelyi, Attila, Ács, Nándor, Lintner, Balázs, Várbíró, Szabolcs, and Keszthelyi, Márton
- Subjects
- *
LEVONORGESTREL intrauterine contraceptives , *RESEARCH protocols , *ENDOMETRIAL cancer , *ENDOMETRIAL hyperplasia , *FERTILITY preservation - Abstract
Endometrial cancer is a leading gynecological malignancy, with obesity being a significant risk factor due to increased estrogen production in body fat. Current treatments often involve hysterectomy, which precludes fertility, thus highlighting the need for fertility-preserving options. This study aims to evaluate the combined efficacy of a levonorgestrel intrauterine device (LNG-IUD), metformin, and liraglutide for treating women with endometrial hyperplasia or early stage endometrial cancer while preserving fertility. The study will enroll 264 women aged 18–45 with a BMI > 30 who desire uterine preservation. Participants will be randomized into three groups: LNG-IUD alone, LNG-IUD plus metformin, and LNG-IUD plus metformin and liraglutide. Primary outcomes will include complete pathological remission, while secondary outcomes will assess histological changes, glucose, insulin levels, and weight changes over a 12-month period. This study protocol hypothesizes that LNG-IUD combined with metformin and liraglutide may potentially lead to higher regression rates of endometrial hyperplasia (EH) and early stage endometrial cancer (EC) compared to LNG-IUD alone. Furthermore, the protocol anticipates that these combination therapies will demonstrate good tolerability with minimal adverse effects, suggesting the potential benefit of integrating metabolic interventions with LNG-IUD to enhance treatment efficacy while preserving fertility in women with EH and EC. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
43. Mismatch repair deficiency and abnormal p53 expression has significant predictive value for progesterone resistance and endometrial tumorigenesis in patients with endometrial atypical hyperplasia receiving fertility-preserving treatment.
- Author
-
Peng, Hongfa, Jiang, Jingjing, Li, Limeng, Hao, Zengfang, Lian, Hongguang, Du, Hui, and Wang, Wei
- Subjects
- *
ENDOMETRIAL hyperplasia , *PROGESTERONE , *POLYCYSTIC ovary syndrome , *DISEASE relapse , *P53 protein , *BODY mass index - Abstract
This study aimed to evaluate the prognostic ability of mismatch repair deficiency (MMR-d) and abnormal p53 expression (p53abn) in patients with endometrial atypical hyperplasia (EAH) who underwent fertility-preserving treatment. This retrospective study evaluated 51 patients with EAH who underwent fertility-sparing treatment. Endometrial biopsy specimens obtained before hormone therapy were collected and used for immunohistochemical staining for MMR and p53 proteins. Response, relapse, and progression rates were assessed based on age, body mass index, diabetes, polycystic ovary syndrome, reproductive history, MMR status, and p53 status. Overall, 11/51 (21.6%) patients had loss of MMR proteins and 6/51 (11.8%) had p53abn. Patients with MMR-d had lower complete response (CR) rates than those with normal staining patients at 12 months after initial treatment (p = 0.049). Patients with MMR-d had significantly higher relapse rates than those with MMR-p at the 1-year follow-ups after achieving CR (p = 0.035). Moreover, patients with MMR-d had a higher incidence of disease progression at 2, 3, and 4 years after fertility-sparing treatment (p = 0.001, p = 0.01 and p = 0.035, respectively). Patients with p53abn had higher relapse rates than those with p53wt at the 1- and 2-year follow-ups after achieving CR (p = 0.047 and p = 0.036, respectively). Moreover, patients with p53abn had a higher incidence of disease progression at 3 and 4 years after fertility-sparing treatment (p = 0.02 and p = 0.049, respectively). EAH patients with MMR-d and p53abn have a significantly higher risk of disease relapse and progression. Thus, MMR-d and p53abn may be used as predictive biomarkers of progestin resistance and endometrial tumorigenesis in EAH. • EAH patients with MMR-d and p53abn have poor outcomes after hormone therapy. • MMR-d and p53abn predicts EAH relapse and progression during fertility-sparing treatment. • MMR-d and p53abn may be used as predictive biomarkers of progestin resistance and endometrial tumorigenesis. • MMR-d and p53abn testing is achievable with biopsy samples, enabling risk stratification from the first diagnosis. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
44. Diagnostic significance and predictive efficiency of metabolic risk score for fertility-sparing treatment in patients with atypical endometrial hyperplasia and early endometrial carcinoma.
- Author
-
Xingchen Li, Yiqin Wang, Jiaqi Wang, Jingyi Zhou, and Jianliu Wang
- Subjects
- *
ENDOMETRIAL hyperplasia , *DISEASE risk factors , *ENDOMETRIAL cancer , *POLYCYSTIC ovary syndrome , *FERTILITY preservation , *BODY mass index - Abstract
Objective: This study aims to assess the impact of the metabolic risk score (MRS) on time to achieve complete remission (CR) of fertility-sparing treatments for atypical endometrial hyperplasia (AEH) and early endometrial cancer (EC) patients. Methods: Univariate and multivariate cox analyses were employed to identify independent risk factors affecting the time to CR with patients at our center. These factors were subsequently incorporated into receiver operator characteristic curve analysis and decision curve analysis to assess the predictive accuracy of time to CR. Additionally, Kaplan--Meier analysis was utilized to determine the cumulative CR rate for patients. Results: The 173 patients who achieved CR following fertility preservation treatment (FPT) were categorized into three subgroups based on their time to CR (<6, 6-9, >9 months). Body mass index (hazard ratio [HR]=0.20; 95% confidence interval [CI]=0.03, 0.38; p=0.026), MRS (HR=0.31; 95% CI=0.09, 0.52; p=0.005), insulin resistance (HR=1.83; 95% CI=0.05, 3.60; p=0.045), menstruation regularity (HR=3.77; 95% CI=1.91, 5.64; p=0.001), polycystic ovary syndrome (HR=-2.16; 95% CI=-4.03, -0.28; p=0.025), and histological type (HR=0.36; 95% CI=0.10, 0.62; p=0.005) were identified as risk factors for time to CR, with MRS being the independent risk factor (HR=0.29; 95% CI=0.02, 0.56; p=0.021). The inclusion of MRS significantly enhanced the predictive accuracy of time to CR (area under the curve [AUC]=0.789 for Model 1, AUC=0.862 for Model 2, p=0.032). Kaplan--Meier survival curves revealed significant differences in the cumulative CR rate among different risk groups. Conclusion: MRS emerges as a novel evaluation system that substantially enhances the predictive accuracy for the time to achieve CR in AEH and early EC patients seeking fertility preservation. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
45. Comparative Assessment of miR-185-5p and miR-191-5p Expression: From Normal Endometrium to High-Grade Endometrial Cancer.
- Author
-
Oropeza-de Lara, Sergio Antonio, Garza-Veloz, Idalia, Berthaud-González, Bertha, Tirado-Navarro, Tania Guillermina, Gurrola-Carlos, Reinaldo, Bonilla-Rocha, Bernardo, Delgado-Enciso, Ivan, and Martinez-Fierro, Margarita L.
- Subjects
- *
ENDOMETRIAL cancer , *ENDOMETRIAL hyperplasia , *TUMOR markers , *CARCINOGENESIS , *BIOMARKERS - Abstract
Endometrial cancer (EC) is a significant cause of cancer-related deaths in women. MicroRNAs (miRs) play a role in cancer development, acting as oncogenes or tumor suppressors. This study evaluated the diagnostic potential of hsa-miR-185-5p and hsa-miR-191-5p in EC and their correlation with clinical and histopathological features. A cross-sectional study analyzed formalin-fixed, paraffin-embedded tissue samples from 59 patients: 18 with EC, 21 with endometrial hyperplasia (EH), 17 with normal endometrium (NE), and 3 with endometrial polyps (EPs). Quantitative reverse transcription-polymerase chain reaction and TaqMan probes were used for miR expression analysis. The Shapiro–Wilk test was used to analyze the normal distribution of the data. Subsequently, parametric or non-parametric tests were used to evaluate the associations between the expression levels of each miR and clinical parameters. Both miRs were underexpressed in some precursor and malignant lesions compared to certain NE subtypes and benign lesions. Specifically, hsa-miR-185-5p showed underexpression in grade 3 EC compared to some NE and EH subtypes (FC: −57.9 to −8.5, p < 0.05), and hsa-miR-191-5p was underexpressed in EH and EC compared to secretory endometrium and EPs (FC: −4.2 to −32.8, p < 0.05). SETD1B, TJP1, and MSI1 were common predicted target genes. In conclusion, hsa-miR-185-5p and hsa-miR-191-5p are underexpressed in EC tissues, correlating with histopathological grades, highlighting their potential as diagnostic biomarkers and their role as tumor suppressors in EC. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
46. STUDY ON HISTOPATHOLOGICAL ANALYCIS AT ENDOMETRIUM PATTERN IN PERI-MENOPAUSE PATIENT WITH ABNORMAL UTERINE BLEEDING.
- Author
-
Iqbal Mansuri, Salehabanu Mahmad, Shrivastawa, Namrata, and Parveen, Nusrat
- Subjects
- *
ENDOMETRIAL hyperplasia , *UTERINE hemorrhage , *ENDOMETRIUM , *HISTOPATHOLOGY , *DILATATION & curettage , *PERIMENOPAUSE , *SYMPTOMS - Abstract
Background:Abnormal uterine bleeding (AUB) is a very common gynaecological condition that affects women of all age groups. Majority of the cases are diagnosed by sampling the endometrium by procedure like dilatation & curettage and performed histopathology. Objectives:The aim of the study was to evaluate the histopathological pattern of endometrium in perimenopausal women presenting with abnormal uterine bleeding Methods: This was a prospective cross sectional study. A total of 150 perimenopausal women aged 40-48 years have been taken having considered appropriate within the inclusion criteria. Endometrial samples were obtained from D & C material collected in 10% formalin and sent for histopathological analysis. Histopathological endometrial patterns were recorded. Results: Most of the patients were between 40-44 years of age (62.7%) and menorrhagia was the dominant clinical presentation (42%). Majority of the women was comes after 6-12 months of symptoms. Majority of them were multiparous (92%). The commonest pathology was endometrial hyperplasia in 42.7%, women with simple hyperplasia without atypia being the predominant pattern (34%). Proliferative endometrium was the second most common finding (20%). Other pathology identified was secretory endometrium (17.7%), atrophic endometrium (8%), endometritis (4%), endometrial polyp (3.3%) and endometrial carcinoma in 2.6% of cases. Conclusion: Endometrial hyperplasia was the most common histopathological finding in AUB among perimenopausal women.Thus, it is important to use histopathological examination as a complementary diagnostic tool in classifying the structural causes of AUB. [ABSTRACT FROM AUTHOR]
- Published
- 2024
47. Intermediate-risk endometrial cancer treated with adjuvant brachytherapy using single dosimetric planning: long-term outcome and toxicity assessment.
- Author
-
Cordoba, Abel, El Hajj, Houssein, Escande, Alexandre, Scouarnec, Cyrielle, Narducci, Fabrice, Martinez Gomez, Carlos, Leblanc, Eric, Hudry, Delphine, Pasquesoone, Camille, Taieb, Sophie, Mirabel, Xavier, Lartigau, Eric F., and Le Tinier, Florence
- Subjects
- *
ENDOMETRIAL cancer , *MEDICAL dosimetry , *RADIOISOTOPE brachytherapy , *PROGNOSIS , *OVERALL survival , *ENDOMETRIAL hyperplasia - Abstract
• Vaginal brachytherapy remains the main treatment for intermediate operated endometrial cancer, with very low rates of local relapse and an acceptable toxicity profile. Brachytherapy of the vaginal dome is the recommended adjuvant treatment for intermediate-risk endometrial cancer. This study assessed the results of dosimetric planning of high-dose-rate brachytherapy exclusively in the first treatment session. Study design: This retrospective study included all patients who underwent hysterectomy for endometrial cancer followed by adjuvant brachytherapy of the vaginal dome between 2012 and 2015. Local recurrence rates, overall survival (OS) rates, recurrence-free survival (RFS) rates, and related acute and late toxicity rates were evaluated. This analysis included 250 patients, of whom 208 were considered to be at high–intermediate risk of disease recurrence. After a median follow-up of 56 months, the cumulative incidence of local recurrence was 4.8% at 3 years [95% confidence interval (CI) 2.8–8.3] and 7.8% at 5 years (95% CI 4.8–12.6). The 5-year OS rate was 86.2% (95% CI 80.6–90.3), and the 5-year RFS rate was 77.5% (95% CI 71.1–82.7). Acute toxicity occurred in 20 (8%) patients, of which two patients had grade ≥3 toxicity. Only one patient (0.4%) presented with late grade ≥3 toxicity. These findings confirm the tolerability of this brachytherapy approach, indicating minimal cases of late grade ≥3 toxicity, associated with a good 5-year OS rate. With the advent of molecular prognostic factors, the current focus revolves around discerning those individuals who gain the greatest benefit from adjuvant therapy, and tailoring treatment more effectively. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
48. Bcl-2 May Contribute to Evolution of Endometrial Hyperplasia, but It Isn’t a Factor in Subsequent Carcinogenesis.
- Author
-
Krishna Kumar, K. T. A., Upadhyaya, K., and R. T. C. N.
- Subjects
ENDOMETRIAL hyperplasia ,NEOPLASTIC cell transformation ,ENDOMETRIAL cancer ,PRECANCEROUS conditions ,IMMUNOSTAINING ,ENDOMETRIUM - Abstract
Endometrial carcinoma is a prevalent disease in the Western world and is experiencing an upward trend in developing countries as well. Endometrial hyperplasia is regarded as a precancerous lesion. Apoptosis plays an important role in the neoplastic transformation of cells, with Bcl-2 serving as an anti-apoptotic cellular marker. It is possible that Bcl-2 may plays an important role in the development of endometrial carcinoma. The objective was to evaluate and compare the expression of the Bcl-2 markers accross the spectrum of normal endometrium endometrial hyperplasia and endometrial adenocarcinoma. A total of 50 cases were included in this study, comprising of 10 cases of normal endometrium, 10 cases of endometrial hyperplasia without atypia, 10 cases of atypical endometrial hyperplasia and 20 cases of endometrial adenocarcinomas. The cases were collected from January 2017 to June 2018. Immunohistochemical staining with Bcl-2 was performed and the results were subsequently analyzed. Bcl-2 staining demonstrated a notable increase in cases exhibiting with strong staining intensity, from 20% in normal endometrial tissue to 75% in cases of endometrial hyperplasia. However, there was a notable decline in the number of cases exhibiting with strong intensity Bcl-2 staining as the lesions progressed from endometrial hyperplasia to endometrial carcinoma (30% of the cases). The results were statistically significant (P =0.00309). However, there was no significant association was observed between staining and either atypical hyperplasia or endometrial carcinomas (p=0.429), or between the degree of carcinoma and staining (p=0.6903). Bcl-2 expression demonstrated an increase from cases of normal endometrium to endometrial hyperplasia, which supports the hypothesis that there is an increase in anti-apoptotic activity in endometrial hyperplastic lesions. The observed decrease in Bcl-2expression in endometrioid adenocarcinoma when compared to endometrial hyperplasia may indicate the involvement of alternative mechanisms of carcinogenesis, potentially beyond the failure of apoptosis. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
49. Genetic and epigenetic alterations in precursor lesions of endometrial endometrioid carcinoma.
- Author
-
Gotoh, Osamu, Sugiyama, Yuko, Tonooka, Akiko, Kosugi, Mayuko, Kitaura, Sunao, Minegishi, Ryu, Sano, Masatoshi, Amino, Sayuri, Furuya, Rie, Tanaka, Norio, Kaneyasu, Tomoko, Kumegawa, Kohei, Abe, Akiko, Nomura, Hidetaka, Takazawa, Yutaka, Kanao, Hiroyuki, Maruyama, Reo, Noda, Tetsuo, and Mori, Seiichi
- Subjects
ENDOMETRIAL hyperplasia ,ENDOMETRIAL cancer ,NEOPLASTIC cell transformation ,EPIGENETICS ,DNA microarrays ,PTEN protein ,METHYLATION - Abstract
The hyperplasia–carcinoma sequence is a stepwise tumourigenic programme towards endometrial cancer in which normal endometrial epithelium becomes neoplastic through non‐atypical endometrial hyperplasia (NAEH) and atypical endometrial hyperplasia (AEH), under the influence of unopposed oestrogen. NAEH and AEH are known to exhibit polyclonal and monoclonal cell growth, respectively; yet, aside from focal PTEN protein loss, the genetic and epigenetic alterations that occur during the cellular transition remain largely unknown. We sought to explore the potential molecular mechanisms that promote the NAEH–AEH transition and identify molecular markers that could help to differentiate between these two states. We conducted target‐panel sequencing on the coding exons of 596 genes, including 96 endometrial cancer driver genes, and DNA methylome microarrays for 48 NAEH and 44 AEH lesions that were separately collected via macro‐ or micro‐dissection from the endometrial tissues of 30 cases. Sequencing analyses revealed acquisition of the PTEN mutation and the clonal expansion of tumour cells in AEH samples. Further, across the transition, alterations to the DNA methylome were characterised by hypermethylation of promoter/enhancer regions and CpG islands, as well as hypo‐ and hyper‐methylation of DNA‐binding regions for transcription factors relevant to endometrial cell differentiation and/or tumourigenesis, including FOXA2, SOX17, and HAND2. The identified DNA methylation signature distinguishing NAEH and AEH lesions was reproducible in a validation cohort with modest discriminative capability. These findings not only support the concept that the transition from NAEH to AEH is an essential step within neoplastic cell transformation of endometrial epithelium but also provide deep insight into the molecular mechanism of the tumourigenic programme. © 2024 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
50. Impact of abnormal uterine bleeding care in premenopausal patients prior to endometrial malignancy diagnosis.
- Author
-
Grubman, Jessica, Mora, Vanessa, Nguyen, May, Ladwig, Nicholas, Jacoby, Vanessa, and Chen, Lee-may
- Subjects
Abnormal uterine bleeding ,Access to care ,Endometrial cancer ,Endometrial hyperplasia - Abstract
BACKGROUND: Literature evaluating the management of abnormal uterine bleeding in premenopausal patients prior to endometrial malignancy diagnosis is lacking. OBJECTIVE: To evaluate predictors and consequences of inadequate evaluation and management of abnormal uterine bleeding and time to endometrial sampling in premenopausal patients prior to endometrial malignancy diagnosis.Study Design.This was a retrospective cohort study of premenopausal individuals with endometrioid endometrial cancer or atypical hyperplasia at a single institution from 2015 to 2020.. Complete noninvasive management encompassed pelvic exam, ultrasound, and progestin treatment before or in conjunction with the endometrial sampling of diagnosis. Multivariable logistic and ordinal odds models were used to evaluate predictors and outcomes. RESULTS: 152 subjects were included, 80.3 % with cancer and 19.7 % with atypical hyperplasia. The majority of patients had anovulatory bleeding, obesityand recent health care. Only 20.4 % had complete nonvinvasive management, and only 12.5 % had complete noninvasive management or endometrial sampling within 2 months of presentation with abnormal bleeding. Class III obesity reduced the likelihood of complete assessment and increased time to sampling, while age 45 and up and parity reduced time to sampling. Most patients had partial workup but no progestin treatment and long intervals before endometrial sampling after presentation to a provider with abnormal bleeding. Incomplete workup correlated to worse cancer grade and stage. CONCLUSION: Despite high clinical risk and health care contact, most patients had insufficient gynecologic management preceding a diagnosis of endometrial malignancy. Inadequate care correlated to worse oncologic outcomes and demonstrates missed opportunities for early detection and prevention of endometrial cancer.
- Published
- 2023
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.